eShowcase: LabPas CT 2.5
Phase I package adds formulary accountability, recruitment, lab, and EDC features
Phase I package adds formulary accountability, recruitment, lab, and EDC features
LabPas CT 2.5
Green Mountain Logic (Montpellier, VT) has added formulary accountability, recruitment, clinical lab, and EDC components to LabPas CT, its software package designed for Phase I management. LabPas CT 2.5 deploys PDAs on clinic floors for scanning patient and collection vessel barcodes and RFIDs to eliminate error potential. It provides real-time electronic data entry for collection times, comments, dosing, vital signs, and adverse events, and can adapt to changing protocols.
Enhancements in the latest version of LabPas CT allow users to track and manage the entire fomulary chain including accountability, distribution, reconciliation, returns, and destruction. The package also allows users to manage subject information such as biometrics, and handles scheduling and study assignment tasks. Also, the new clinical lab component of LabPas CT integrates clinical trial results into the study database, and the software exports clinical study data in a variety of formats for easy eCRF creation.
Green Mountain Logic, (866) LABPAS1, www.labpas.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
